Terapia personalizada en la enfermedad inflamatoria intestinal

dc.coverageDOI: 10.1016/j.gastrohep.2023.12.006
dc.creatorCalderón, Paula
dc.creatorNúñez, Paulina
dc.creatorNos, Pilar
dc.creatorQuera, Rodrigo
dc.date2024
dc.date.accessioned05-01-2026 18:14
dc.date.available05-01-2026 18:14
dc.description<p>Inflammatory bowel diseases (IBD), with ulcerative colitis and Crohn's disease being their most common presentations, comprise a spectrum of diverse disease phenotypes, exhibiting variable behaviors ranging from an indolent course to aggressive phenotypes that impact quality of life of these patients. The last two decades have been marked by the development of new medications (biological therapy and novel small molecules) with diverse mechanisms of action, which have revolutionized the management of IBD, thereby enhancing the quality of life for these patients. This landscape of multiple therapeutic options underscores the need to define which medication will benefit each patient the most and at what speed it should be started. The objective of this review is to present personalized approaches for patients with IBD, thus contributing to therapeutic management.</p>eng
dc.identifierhttps://investigadores.uandes.cl/en/publications/552d462b-3448-4e02-820c-8b7a2736c7c3
dc.languagespa
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.sourcevol.47 (2024) date: 2024-08-01 nr.7 p.763-770
dc.subjectInflammatory bowel diseases
dc.subjectMonitoring
dc.subjectPersonalized
dc.subjectTreat to target
dc.titleTerapia personalizada en la enfermedad inflamatoria intestinalspa
dc.titlePersonalized therapy in inflammatory bowel diseaseeng
dc.titleTerapia personalizada en la enfermedad inflamatoria intestinalspa
dc.typeReview articleeng
dc.typeArtículo de revisiónspa
Files
Collections